
Recently stung by AAV, Sarepta dives a little deeper into non-viral delivery with newest licensing pact
The use of adeno-associated viruses (AAV) as delivery vehicles for gene therapeutics has been riddled with safety concerns for years — a fact Sarepta knows well. Now, the pharma has inked a deal with a non-viral delivery player it hopes can sidestep those concerns altogether.
Sarepta will pay out $57 million in near-term cash, as well as research payments and “significant” downstream milestones for access to GenEdit’s polymer nanoparticles, a non-viral delivery mechanism for the company’s gene editing therapies, the partners said Tuesday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,400+ biopharma pros reading Endpoints daily — and it's free.